Asset Details
Do you wish to reserve the book?
CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
Do you wish to request the book?
CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
2021
Overview
[...]some of its characteristics such as its low bioavailability, low metabolic stability and off-target effects limit its therapeutic use (Ghoteimi et al., 2019). Some natural products capable of inhibiting CD73 have been reported to possess biological effects that include anticancer activities (Braganhol et al., 2007;Rockenbach et al., 2013). Recently, extensive studies of structure-activity relationships, structure-based drug design, and the optimization of pharmacokinetic properties culminated in the discovery of several different APCP analogues. [...]nucleoside analogues with two carboxylate groups and benzothiazine derivatives are CD73 inhibitors for treating cancer that have been patented (Gong et al., 2018;Ghoteimi et al., 2019).
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.